一项关于卡维地洛抗纤颤作用的安慰剂对照评估。
A placebo controlled evaluation of the antifibrillatory effects of carvedilol.
作者信息
Xie J, Dunn A, Tsikouris J P, Sun Y, Fan C, Kluger J, Chow M S, White C M
机构信息
Department of Pharmacy, Hartford Hospital, CT 06102-5037, USA.
出版信息
J Electrocardiol. 2001 Jan;34(1):25-30. doi: 10.1054/jelc.2001.22032.
This article evaluates the antifibrillatory effects of carvedilol 5 mg/kg and vehicle (dimethyl-formamide) over time. Sprague-Dawley rats were anesthetized and intubated. They underwent baseline ventricular fibrillation threshold (VFT) determination and then received 1 of the 2 treatments (n = 10/group) over 8 minutes. VFT and determinations were performed at 2, 7, 15, 30, 45, and 60 minutes postinfusion. Carvedilol significantly increased the VFT at 2, 7, 15, 30 minutes versus baseline and the vehicle control group. Carvedilol significantly reduced the heart rate and the mean arterial pressure at every evaluable time point versus baseline and vehicle control. Carvedilol showed significant antifibrillatory effects versus baseline and vehicle for the first 30 minutes but not thereafter, even though the heart rate and mean arterial pressure remain significantly reduced.
本文评估了5毫克/千克卡维地洛和赋形剂（二甲基甲酰胺）随时间推移的抗纤颤作用。将斯普拉格-道利大鼠麻醉并插管。它们接受基线室颤阈值（VFT）测定，然后在8分钟内接受两种治疗中的一种（每组n = 10）。在输注后2、7、15、30、45和60分钟进行VFT测定。与基线和赋形剂对照组相比，卡维地洛在2、7、15、30分钟时显著提高了VFT。与基线和赋形剂对照组相比，卡维地洛在每个可评估时间点均显著降低了心率和平均动脉压。卡维地洛在最初30分钟内相对于基线和赋形剂显示出显著的抗纤颤作用，但此后则没有，尽管心率和平均动脉压仍显著降低。
Zotero 插件